Insights & opinions from RA Capital Management

11/22/22

I walked 100 miles for this term sheet

Biotech

Culture

Finance

11/16/22

Transforming Forma — The Science of Giving a Damn

Biotech

Culture

Finance

10/31/22

Alnylam is doing what the IRA is telling it to do

Biotech

Finance

Policy

09/21/22

Saving money for Medicare by abandoning new drugs for Medicare patients

Biotech

Finance

Policy

09/16/22

COVID-19: When RA Capital’s ​“secret” maps go public

Biotech

Culture

08/26/22

Navigating a storm that threatens American biotechnology

Biotech

Policy

08/24/22

GoodRx collaborating with RA Capital on Survey to Better Understand Patient Assistance Programs

Science

08/11/22

The NIH, R&D, and the first mile of the marathon — a conversation with John LaMattina

Biotech

Policy

08/03/22

When life-saving medication should be in aisle three

Biotech

Policy

07/28/22

Innovation and biopharma M&A: feature, not bug

Biotech

Policy

07/13/22

Post-launch, pre-cliff: The R&D Congress ignores

Policy

Biotech

07/08/22

Biotech leaders urge fixes to bad Senate drug deal

Biotech

Policy

06/23/22

How to kill the conversation that makes innovation possible

Biotech

Policy

06/16/22

Right to Try 2.0 doubles down on a bad idea

Biotech

Policy

06/10/22

72 hours to kill: Why can’t we diagnose bacterial infections faster?

Biotech

Science

05/31/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn (Bionic Reading)

Finance

05/27/22

Biotech’s Dulcius Ex Asperis: The Way Through This Downturn

Biotech

Finance

05/25/22

Step-by-step price discovery for private companies

Finance

05/12/22

Announcing RA University: IV League Biotech

Culture

05/02/22

Letter to my ex: The office

Culture